Michael Henderson
Vermögen: 97 Mio $ am 31.05.2026
Vermögen: 97 Mio $ am 31.05.2026
Michael Henderson gründete PellePharm, Inc. Er ist Chief Executive Officer bei QED Therapeutics, Inc. und Chief Executive Officer bei Origin Biosciences, Inc. sowie Chief Business Officer bei BridgeBio Pharma, Inc. und sitzt im Vorstand von 5 weiteren Unternehmen. In der Vergangenheit hatte er die Position eines Senior Associate bei McKinsey & Co. inne. Dr. Henderson erhielt einen Bachelor-Abschluss von der Harvard University und einen Doktortitel von der Stanford University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.06.2026 | 1 095 987 ( 1,96 % ) | 90 Mio $ | 31.05.2026 | |
| 27.05.2026 | 88 606 ( 0,1 % ) | 7 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 22.06.2023 |
| APOGEE THERAPEUTICS, INC. | Vorstandsvorsitzender | 01.09.2022 |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Vorstandsvorsitzender | - |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Vorstandsvorsitzender | - |
Therasis, Inc.
Therasis, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology drugs | Direktor/Vorstandsmitglied | 01.09.2016 |
Adrenas Therapeutics, Inc. | Direktor/Vorstandsmitglied | 01.07.2017 |
Quartz Therapeutics, Inc. | Direktor/Vorstandsmitglied | 01.09.2016 |
| Unternehmen | Position | Ende |
|---|---|---|
| ARYA SCIE | Direktor/Vorstandsmitglied | 01.08.2024 |
| BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 01.09.2022 |
| ░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 13 |
|---|---|
Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company | Health Technology |
PellePharm, Inc.
PellePharm, Inc. BiotechnologyHealth Technology Develops biotechnologies to cure dermatological diseases | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Therasis, Inc.
Therasis, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology drugs | Health Technology |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Quartz Therapeutics, Inc. | |
Adrenas Therapeutics, Inc. | |
ARYA Sciences Acquisition Corp. IV
ARYA Sciences Acquisition Corp. IV Financial ConglomeratesFinance Operates as a blank check company | Finance |
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops therapies for immunological and inflammatory disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen